research use only
Cat.No.S5645
| Related Targets | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Other Heme Oxygenase Inhibitors | Tin protoporphyrin IX dichloride Fraxetin Ferulaldehyde Momordica grosvenori Extract |
|
In vitro |
DMSO
: 20 mg/mL
(30.67 mM)
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 651.94 | Formula | C34H32ClFeN4O4 |
Storage (From the date of receipt) | 3 years -20°C(in the dark) powder |
|---|---|---|---|---|---|
| CAS No. | 16009-13-5 | -- | Storage of Stock Solutions |
|
|
| Synonyms | protohemin | SMILES | CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)O)CCC(=O)O.[Cl-].[Fe+3] | ||
Read more about storage stability CAS number SMILES
| In vitro |
Treatment of hemin or AFC damped the expression of TFRC in CT26 cells, which can be significantly rescued by overexpression of OTUD1. |
|---|---|
| In vivo |
Following the i.p. administration of Hemin (100 μM/kg), the HO-1 level in the renal cortex begins to increase gradually. The HO-1 level reaches its peak 24 h after this compound preconditioning. HO-1 is expressed mainly in the renal tubules. The HO-2 level in the kidney does not change following this chemical preconditioning. |
References |
(data from https://clinicaltrials.gov, updated on 2026-01-30)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02922413 | TERMINATED | Acute Intermittent Porphyria; Hereditary Coproporphyria; Variegate Porphyria |
The University of Texas Medical Branch, Galveston |
2015-10-30 | PHASE2 |
| NCT01855841 | COMPLETED | Post-ERCP Acute Pancreatitis |
Erasme University Hospital |
2012-04 | PHASE2 |
| NCT03338816 | Completed | Acute Hepatic Porphyria|Acute Intermittent Porphyria|Porphyria Acute Intermittent|Acute Porphyria|Hereditary Coproporphyria (HCP)|Variegate Porphyria (VP)|ALA Dehydratase Deficient Porphyria (ADP) |
Alnylam Pharmaceuticals |
2017-11-16 | Phase 3 |
| NCT02949830 | Completed | Acute Intermittent Porphyria |
Alnylam Pharmaceuticals |
2016-10 | Phase 1|Phase 2 |
| NCT01206582 | COMPLETED | Gastroparesis; Diabetes Mellitus |
Mayo Clinic |
2010-05 | PHASE2 |
| NCT01855841 | Completed | Post-ERCP Acute Pancreatitis |
Erasme University Hospital |
2012-04 | Phase 2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.